A lot has been going on in the CRISPR world. Here are some key CRISPR updates. Editas has filed the paperwork on the road to going public as a company. Such an IPO, should it come to fruition, could raise billions of dollars. Will the other CRISPR companies like Caribou and CRISPR Therapeutics follow suit? Simplistically, […]
New #CRISPR updates: Editas to go public, patent issues, dragons & more Read More »
GOP members of Congress want a ban on CRISPR of human embryos. They are moving to block genetic modification of human embryos using the new CRISPR gene editing technology. The new proposed spending bill part way through the approval process with the nugget of good news of a possible NIH spending boost after many years
GOP Congress seeks ban on CRISPR of human embryos Read More »
The US Congress recently held its first hearing on human germline genetic modification. The meeting included CRISPR-Cas9 pioneer Jennifer Doudna (see video here) on the panel. See image of Cas9 structure from Wikipedia. CRISPR-Cas9 is a powerful, strikingly efficient tool for genetic engineering of cells and whole organisms. Now Republican congressional leaders have included a
Congress: FDA should consult religious experts on embryo CRISPR Read More »
A decade ago I wrote an article in the journal Nature Biotechnology about the rise of a new gene editing technology called zinc finger nucleases (ZNF). It was one of those “drumbeat” discoveries: at the time, my sense was it would revolutionize how we deliver genes to cells and tissues, and profoundly change the way
Guest Post by Chris Scott–The Great CRISPR Controversy: What’s Next? Read More »
Last Thursday I participated in a meeting at Stanford Law School on human germline genetic modification hosted by Hank Greely (pictured at left), Professor of Law and Genetics at Stanford. The meeting was entitled, “Human Germline Modification: Medicine, Science, Ethics, and Law”. The panel included in addition to Hank and me, the following speakers: Marcy Darnovsky, Executive Director of
Stanford Human Germline Modification Meeting: Medicine, Science, Ethics, & Law Read More »
There is a big old blind spot in the discussion over germline gene editing in humans: preimplantation genetic diagnosis (PGD). There’s been a lot of talk in 2015 about worries over how gene editing technology such as CRISPR might be used prematurely in the clinic in an unsafe or unethical manner in humans in the
The big blind spot on CRISPR for human embryo editing: PGD Read More »